Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3831-3837

  Stewart, Zoe A ^a   Mays, Deborah ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE; MICROTUBULE INHIBITOR; PACLITAXEL; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, MOUSE; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DRUG DERIVATIVE; ECDYSTERONE; PONASTERONE A; TUMOR PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENOTOXICITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA; CELL CULTURE; COLON TUMOR; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; MICROTUBULE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA; CDC2 PROTEIN KINASE; COLONIC NEOPLASMS; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ECDYSTERONE; FEMALE; G1 PHASE; MICE; MICE, NUDE; MICROTUBULES; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PACLITAXEL; S PHASE; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0033169231     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Hartwell, L. H., and Weinert, T. A. Checkpoints, Controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629-634, 1989.
2. Kaufmann, W. K., and Paules, R. S. DNA damage and cell cycle checkpoints. FASEB J., 10: 238-247, 1996.
3. Sorger, P. K., Dobles, M., Tournebize, R., and Hyman, A. A. Coupling cell division and cell death to microtubule dynamics. Curr. Opin. Cell Biol., 9: 807-814, 1997.
4. Cohen-Fix, O., and Koshland, D. The metaphase-to-anaphase transition: avoiding a mid-life crisis. Curr. Opin. Cell Biol., 9: 800-806, 1997.
5. Paulovich, A. G., Toczyski, D. P., and Hartwell, L. H. When checkpoints fail. Cell, 88: 315-321, 1997.
6. L and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev., 10: 2621-2631, 1996.
7. Hoyt, M. A., Totis, L., and Roberts, B. T. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell, 66: 507-517, 1991.
8. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cell lacking p21. Nature (Lond.), 381: 713-716, 1996.
9. Di Leonardo, A., Khan, S. H., Linke, S. P., Greco, V., Seidita, G., and Wahl, G. M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res., 57: 1013-1019, 1997.
10. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
11. Lanni, J. S., and Jacks, T. S. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell Biol., 18: 1055-1064, 1998.
12. 1 arrest. Cancer Res., 58: 1396-401, 1998.
13. Waf1/Cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol., 19: 205-215, 1999.
14. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
15. McIlwrath, A. J., Vasey, P. A., Poss, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
16. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res., 54: 5824-5830, 1994.
17. Fan, S., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
18. Smith, M. L., Chen, I-T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr, Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage. Oncogene, 10: 1053-1059, 1995.
19. Fan, S. J., Chang, J. K., Smith, M. L., Duba, D., Fornace, A. J., Jr., and O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14: 2127-2136, 1997.
20. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034-1036, 1997.
21. Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res., 57: 4703-4706, 1997.
22. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y. F., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
23. Trielli, M. O., Andreassen, P. R., Lacroix, F. B., and Margolis, R. L. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J. Cell Biol., 135: 689-700, 1996.
24. Fan, S., Cherney, B., Reinhold, W., Rucker, K., and O'Connor, P. M. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin. Cancer. Res., 4: 1047-1054, 1998.
25. Debernardis, D., Siré, E. G., De Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D'Incalci, M., and Broggini, M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res., 57: 870-874, 1997.
26. Waldman, T., Kinzler, K. W., and Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55: 5187-5195, 1995.
27. Tsujii, M., Kawano, S., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
28. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L., Keefer, C., Leach, S. D., and Pietenpol, J. A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem., 13: 30777-30784, 1998.
29. Davis, F. M., Tsao, T. Y., Fowler, S. K., and Rao, P. N. Monoclonal antibodies to mitotic cells. Proc. Natl. Acad. Sci. USA, 80: 2926-2930, 1983.
30. Reed, J. C. Bcl-2 family proteins. Oncogene, 17: 3225-3236, 1998.
31. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
32. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L., and Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
33. L is phosphorylated in malignant cells following microtubule disruption. Cancer Res., 58: 3331-3338, 1998.
34. Haldar, S., Basu, A., and Croce, C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res., 57: 229-233, 1997.
35. WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
36. Barboule, N., Chadebech, P., Baldin, V., Vidal, S., and Valette, A. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene, 15: 2867-2875, 1997.
37. Cdc2 kinase. Mol. Cell, 2: 581-591, 1998.
38. Ito, T., Deng, X., Carr, B., and May, W. S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem., 272: 11671-11673, 1997.
39. Ling, Y-H., Tornos, C., and Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
40. Andersen, S. S. L. Balanced regulation of microtubule dynamics during the cell cycle: a contemporary view. BioEssays, 21: 53-60, 1999.
41. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblasts cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
42. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 22: 665-667, 1979.
43. De Brabander, M., Geuens, G., Nuydens, R., Willebrodes, R., and DeMey, J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc. Natl. Acad. Sci. USA, 78: 5608-5612, 1981.
44. Jordan, M., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90: 9552-9556, 1993.
45. cdc2 coincident with Taxol-induced apoptosis. Cell Growth Differ., 5: 1041-1050, 1994.
46. cdc2 activation required for apoptosis. Science (Washington DC), 263: 1143-1145, 1994.
47. Chen, G., Shi, L., Litchfield, D. W., and Greenberg, A. H. Rescue from granzyme B-induced apoptosis by Wee1 kinase. J. Exp. Med., 181: 2295-2300, 1995.
48. Meikrantz, W., and Schlegel, R. Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J. Biol. Chem., 271: 10205-10209, 1996.
49. cdc2 kinase for apoptosis mediated by the Fas/APO1 receptor and interleukin 1 β-converting enzyme-related proteases. Cancer Res., 56: 4551-4555, 1996.
50. Leach, S. D., Scatena, C. D., Keefer, C. J., Goodman, H. A., Song, S. Y., Yang, L., and Pietenpol, J. A. Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis. Cancer Res., 58: 3231-3236, 1998.
51. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instabilities in human cancers. Nature (Lond.), 396: 643-649, 1998.
52. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
53. Rowinsky, E. K., and Donehower, R. C. Paclitaxel. N. Engl. J. Med., 15. 1004-1014, 1995.